HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease. The company integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. In addition, HiFiBiO Therapeutics aspires to address unmet medical needs around the world through open-innovation partnerships with industry and academia.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/28/19 | $67,000,000 | Series C |
Delian Capital Hanne Capital IDG Capital Partners  Kite Legend Star LYFE Capital Sequoia China VI Ventures | undisclosed |
| 06/14/21 | $75,000,000 | Series D |
B Capital Group Grand Mount Hengxu HKSTP Venture Fund IDG Capital Partners Legend Star Maison Capital MiraeAsset Financial Group Sherpa Ventures Trinity Innovation Fund | undisclosed |
